Cargando…

(124)I Radiolabeling of a Au(III)‐NHC Complex for In Vivo Biodistribution Studies

Au(III) complexes with N‐heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au(III)‐NHC complexes by direct oxidation with radioactive [(124)I]I(2) as...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarra, Federica, Terenzi, Alessio, Pirker, Christine, Passannante, Rossana, Baier, Dina, Zangrando, Ennio, Gómez‐Vallejo, Vanessa, Biver, Tarita, Gabbiani, Chiara, Berger, Walter, Llop, Jordi, Salassa, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540067/
https://www.ncbi.nlm.nih.gov/pubmed/32633820
http://dx.doi.org/10.1002/anie.202008046
Descripción
Sumario:Au(III) complexes with N‐heterocyclic carbene (NHC) ligands have shown remarkable potential as anticancer agents, yet their fate in vivo has not been thoroughly examined and understood. Reported herein is the synthesis of new Au(III)‐NHC complexes by direct oxidation with radioactive [(124)I]I(2) as a valuable strategy to monitor the in vivo biodistribution of this class of compounds using positron emission tomography (PET). While in vitro analyses provide direct evidence for the importance of Au(III)‐to‐Au(I) reduction to achieve full anticancer activity, in vivo studies reveal that a fraction of the Au(III)‐NHC prodrug is not immediately reduced after administration but able to reach the major organs before metabolic activation.